SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

@article{Conroy2008SNS032IA,
  title={SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples},
  author={Andrew Conroy and David Elliot Stockett and Duncan Walker and Michelle Arkin and Ute R Hoch and Judith Ann Fox and Rachael Elizabeth Hawtin},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2008},
  volume={64},
  pages={723-732}
}
SNS-032 (formerly BMS-387032) is a potent, selective inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9, currently in phase 1 clinical trial for chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). We used the MM cell line RPMI-8226 to evaluate the relationship between duration of SNS-032 exposure, target modulation of CDKs 2, 7 and 9, and induction of apoptosis. We also assessed target modulation in patient peripheral blood mononuclear cells (PBMCs) from phase 1 solid tumor… CONTINUE READING
39 Citations
41 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Mechanism of Action of SNS–032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol

  • R Chen, WG Wierda, S Benaissa
  • ASH Annual Meeting Abstracts
  • 2007
Highly Influential
15 Excerpts

AT7519, a potent CDK inhibitor, is active in leukemia models and primary CLL patient samples

  • MS Squires, RE Feltell, V Lock
  • ASH Annual Meeting Abstracts
  • 2007
Highly Influential
12 Excerpts

Similar Papers

Loading similar papers…